<DOC>
	<DOCNO>NCT02169284</DOCNO>
	<brief_summary>This randomized phase II trial study well erlotinib hydrochloride work treat patient bladder cancer undergo surgery . Erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Erlotinib Hydrochloride Treating Patients With Bladder Cancer Undergoing Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine difference epidermal growth factor receptor ( EGFR ) phosphorylation normal appear bladder epithelium adjacent tumor approximately 9-18 hour post-study dose , patient randomize erlotinib ( erlotinib hydrochloride ) weekly compare placebo . SECONDARY OBJECTIVES : I. Assess tolerance high dose weekly erlotinib compare placebo . II . Assess expression phosphorylated epidermal growth factor ( EGF ) receptor tumor tissue available . III . Assess expression cadherin 1 , type 1 ( e-cadherin ) marker proliferation Ki-67 ( Ki67 ) normal abnormal urothelium . IV . Assess expression phosphorylated extracellular regulated kinase ( ERK ) normal abnormal urothelium . V. Assess limit pharmacokinetics weekly erlotinib . VI . Assess expression tumor protein 53 ( p53 ) normal abnormal urothelium . VII . Assess expression lethal-7 ( let-7 ) normal abnormal urothelium . VIII . Exploratory assessment urination symptom men . OUTLINE : Patients randomize 1 2 treatment group . GROUP I : Patients receive erlotinib hydrochloride orally ( PO ) daily ( QD ) day 1 , 8 , 15 . Patients undergo transurethral resection bladder tumor ( TURBT ) cystectomy day 16 . GROUP II : Patients receive placebo PO QD day 1 , 8 , 15 . Patients undergo TURBT cystectomy day 16 . After completion study treatment , patient follow 7-14 day .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Participants must confirm suspected invasive noninvasive bladder tumor ( initial recurrent ) discover cystoscopy radiologic imaging perform within 120 day randomization Patients muscle invasive bladder cancer ( MIBC ) must never receive currently ineligible cisplatinbased neoadjuvant chemotherapy due following : Calculated creatinine clearance &lt; 60 ml/min Karnofsky performance status ( KPS ) &lt; 80 Solitary kidney Patient refusal undergo neoadjuvant chemotherapy The participant may prior treatment bladder tumor ( exclude radiation therapy ) provide treatment : Was complete great 30 day prior first dose study agent Participants must candidate transurethral resection bladder tumor ( TURBT ) , cystectomy ( partial radical ) cystoscopy biopsy participate organization Karnofsky &gt; = 60 % White blood cell ( WBC ) &gt; = 3000/mm^3 Platelets &gt; = 100,000mm^3 Hemoglobin &gt; 10 g/dL International normalized ratio ( INR ) = &lt; 1.2 Alkaline phosphatase = &lt; upper limit normal Bilirubin = &lt; upper limit normal Aspartate aminotransferase ( AST ) = &lt; 1.5 x upper limit normal Alanine aminotransferase ( ALT ) = &lt; 1.5 x upper limit normal A calculated creatinine clearance ( Cockcroft Gault ) &gt; = 30 ml/min Sodium &gt; = 130 mg/dl = &lt; upper limit normal Potassium &gt; = 3.0 mg/dl = &lt; upper limit normal Calcium = &lt; 11.2 mg/dl Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform study physician immediately Ability understand willingness sign write informed consent document Any treatment bladder tumor intravesical therapy prestudy cystoscopy radiologic image identify suspected bladder tumor schedule surgical removal cystoscopyguided biopsy tumor Any evidence cancer ( exclude nonmelanoma skin cancer ) metastatic disease ; suspect local lymph node involvement allow Any prior pelvic radiation A concurrent skin rash skin condition require treatment prescription medication Concurrent systemic chemotherapy cancer The following medication may take within 24 hour first dose study agent time participant take study agent Strong cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitor include ketoconazole , atazanavir , boceprevir , ceritinib , clarithromycin , cobicistat , darunavir , dasabuvir , idelalisib , indinavir , itraconazole , lopinavir , nefazodone , nelfinavir , ombitasvir , paritaprevir , posaconazole , ritonavir , saquinavir , telithromycin , troleandomycin , voriconazole , grapefruit grapefruit juice CYP3A4 inducer include rifampicin , rifabutin , rifapentine , phenytoin , carbamazepine , phenobarbital , primidone , enzalutamide , fosphenytoin , lumacaftor , mitotane , St. John 's wort Agents decrease gastric acid allow avoid possible Participants may resume inhibitor inducer CYP3A4 &gt; 14 day last dose study agent Participants require daily use nonsteroidal antiinflammatory drug ( NSAIDs ) , exception = &lt; 81 mg aspirin per day ; study participation , acetaminophen prefer treatment pain ; use NSAIDs , need pain , discourage Participants may receive investigational agent History allergic reaction attribute compound similar chemical biologic composition erlotinib clindamycin ( topical agent potential skin toxicity ) An underlying predisposition rectal gastrointestinal bleeding uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Females pregnant lactate may participate study ; female childbearing potential must negative pregnancy test start study agent ; patient bilateral oophorectomy , hysterectomy , great 1 year since last menses consider childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>